Liver disease-associated keratin 8 and 18 mutations modulate keratin acetylation and methylation.
Acetylation
Amino Acid Sequence
Amino Acid Substitution
Animals
Binding Sites
/ genetics
Cell Line
Cricetinae
HT29 Cells
Humans
Keratin-18
/ chemistry
Keratin-8
/ chemistry
Liver Diseases
/ genetics
Mallory Bodies
/ metabolism
Methylation
Mutant Proteins
/ chemistry
Mutation, Missense
Protein Processing, Post-Translational
Protein Stability
Tandem Mass Spectrometry
MDB
intermediate filament
post-translational modification
protein stability
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
pubmed:
15
6
2019
medline:
2
6
2020
entrez:
15
6
2019
Statut:
ppublish
Résumé
Keratin 8 (K8) and keratin 18 (K18) are the intermediate filament proteins whose phosphorylation/transamidation associate with their aggregation in Mallory-Denk bodies found in patients with various liver diseases. However, the functions of other post-translational modifications in keratins related to liver diseases have not been fully elucidated. Here, using a site-specific mutation assay combined with nano-liquid chromatography-tandem mass spectrometry, we identified K8-Lys108 and K18-Lys187/426 as acetylation sites, and K8-Arg47 and K18-Arg55 as methylation sites. Keratin mutation (Arg-to-Lys/Ala) at the methylation sites, but not the acetylation sites, led to decreased stability of the keratin protein. We compared keratin acetylation/methylation in liver disease-associated keratin variants. The acetylation of K8 variants increased or decreased to various extents, whereas the methylation of K18-del65-72 and K18-I150V variants increased. Notably, the highly acetylated/methylated K18-I150V variant was less soluble and exhibited unusually prolonged protein stability, which suggests that additional acetylation of highly methylated keratins has a synergistic effect on prolonged stability. Therefore, the different levels of acetylation/methylation of the liver disease-associated variants regulate keratin protein stability. These findings extend our understanding of how disease-associated mutations in keratins modulate keratin acetylation and methylation, which may contribute to disease pathogenesis.-Jang, K.-H., Yoon, H.-N., Lee, J., Yi, H., Park, S.-Y., Lee, S.-Y., Lim, Y., Lee, H.-J., Cho, J.-W., Paik, Y.-K., Hancock, W. S., Ku, N.-O. Liver disease-associated keratin 8 and 18 mutations modulate keratin acetylation and methylation.
Identifiants
pubmed: 31199680
doi: 10.1096/fj.201800263RR
pmc: PMC6988862
doi:
Substances chimiques
KRT18 protein, human
0
KRT8 protein, human
0
Keratin-18
0
Keratin-8
0
Mutant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9030-9043Références
Mol Cell Proteomics. 2014 Jan;13(1):372-87
pubmed: 24129315
Nat Commun. 2015 Sep 30;6:8419
pubmed: 26420673
J Hepatol. 2003 Apr;38(4):387-94
pubmed: 12663227
J Cell Biol. 1990 Apr;110(4):1199-210
pubmed: 1691189
Science. 2009 Aug 14;325(5942):834-40
pubmed: 19608861
Dev Cell. 2018 Apr 23;45(2):262-275.e8
pubmed: 29689199
Mol Biosyst. 2013 Sep;9(9):2231-47
pubmed: 23748837
Hepatology. 2007 Jan;45(1):88-96
pubmed: 17187412
FASEB J. 2012 Jun;26(6):2318-26
pubmed: 22362895
Hepatology. 2015 Sep;62(3):876-86
pubmed: 25963979
Biochemistry. 1997 Apr 29;36(17):5185-92
pubmed: 9136880
Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50
pubmed: 25053359
J Med Chem. 2016 Oct 13;59(19):9124-9139
pubmed: 27584694
Mol Cell. 2017 Mar 2;65(5):900-916.e7
pubmed: 28238654
J Biol Chem. 1997 Jul 11;272(28):17565-73
pubmed: 9211903
Chem Rev. 2018 Feb 14;118(3):989-1068
pubmed: 28338320
J Cell Biol. 2000 May 1;149(3):547-52
pubmed: 10791969
EMBO J. 2012 Apr 4;31(7):1785-97
pubmed: 22327218
Mol Cell Proteomics. 2003 Dec;2(12):1319-30
pubmed: 14534352
Exp Mol Pathol. 2017 Feb;102(1):106-114
pubmed: 28089901
Biochim Biophys Acta. 2008 Dec;1782(12):764-74
pubmed: 18805482
J Clin Invest. 2009 Jul;119(7):1772-83
pubmed: 19587452
Mol Cell. 2009 Jan 16;33(1):1-13
pubmed: 19150423
Trends Biochem Sci. 2006 Jul;31(7):383-94
pubmed: 16782342
Hepatology. 2009 Aug;50(2):546-54
pubmed: 19585610
Science. 2007 Jul 27;317(5837):516-9
pubmed: 17588900
Oncogene. 2011 May 19;30(20):2379-89
pubmed: 21242974
Nat Cell Biol. 2010 Sep;12(9):876-85
pubmed: 20729838
Gastroenterology. 2010 Sep;139(3):828-35, 835.e1-3
pubmed: 20538000
J Cell Biol. 2006 Jul 3;174(1):115-25
pubmed: 16818723
Nat Rev Mol Cell Biol. 2003 Dec;4(12):938-47
pubmed: 14685172
Hepatology. 2016 Sep;64(3):966-76
pubmed: 26853542
Science. 2010 Feb 19;327(5968):1000-4
pubmed: 20167786
J Clin Invest. 2009 Jul;119(7):1794-805
pubmed: 19587454
Mol Cell. 2006 Aug;23(4):607-18
pubmed: 16916647
J Cell Biol. 2006 Jul 17;174(2):169-74
pubmed: 16831889
Nat Rev Genet. 2009 Jan;10(1):32-42
pubmed: 19065135
J Clin Biochem Nutr. 2011 Jan;48(1):96-100
pubmed: 21297920
Nat Rev Mol Cell Biol. 2014 Mar;15(3):163-77
pubmed: 24556839
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G628-G634
pubmed: 28360031
J Cell Biol. 1996 Apr;133(2):345-57
pubmed: 8609167
J Immunol. 2004 Jun 1;172(11):6744-50
pubmed: 15153491
Curr Opin Gastroenterol. 2012 May;28(3):209-16
pubmed: 22450891
Nat Biotechnol. 2015 Apr;33(4):415-23
pubmed: 25751058
Methods Cell Biol. 2004;78:489-517
pubmed: 15646629
Exp Cell Res. 2007 Jun 10;313(10):2033-49
pubmed: 17531973
FEBS J. 2010 May;277(9):2096-108
pubmed: 20345902
J Cell Biol. 2013 Feb 4;200(3):241-7
pubmed: 23358244
Hepatology. 2007 Nov;46(5):1639-49
pubmed: 17969036
Gastroenterology. 2005 Sep;129(3):885-93
pubmed: 16143128
J Clin Invest. 2009 Jul;119(7):1763-71
pubmed: 19587451